Highlights in myasthenia gravis from AAN 2025 include trials of new therapy inebilizumab, new data on the approved ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Generalized myasthenia gravis (gMG) affects most patients through ... Emotional and physical stress, surgical procedures, ...

Dr Nicholas Silvestri reflects on promising new and existing treatment options, reinforcing a personalized approach and ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...